1. What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?

3. Program Goals

4. Program Overview

5. Intensifying Diabetes Therapy In Patients Already On Basal Insulin: Challenge

6. "Maximum" Dose of Basal Insulin

7. Combination Injectable Therapy: Evidence-Based Recommendations

8. Time From Initiation of Basal Insulin to Intensification in Clinically Eligible Patients*

9. Treatment for Hyperglycemia Changes Over Time in Patients With T2DM

10. "Maximum" Dose of Basal Insulin (cont)

11. Achieving Glycemic Control

12. Relative Contributions of FPG and PPG to HbA1c

13. Basal Insulin/GLP-1 RA FRC Agents

14. LixiLan-L Trial: Key Results

15. DUAL V: Key Results

16. CVOTs With GLP-1 RAs

17. Mechanism of Action of GLP-1 RAs

18. Nutrition Therapy in Patients With T2DM

19. Benefits of Adding a GLP-1 RA to Basal Insulin vs Adding Prandial Insulin

20. Cost-Effectiveness of FRC Therapy: Data From DUAL V

21. Integrating Basal Insulin/GLP-1 RA FRC Therapy Into Primary Care: Challenges

22. Basal Insulin/GLP-1 RA FRC Agents

23. Integrating Basal Insulin/GLP-1 RA FRC Therapy Into Primary Care: Challenges (cont)

24. Mean Daily Dose of Basal Insulin Significantly Lower With FRC Therapy

25. Fewer Adverse GI Events With FRC Agents vs GLP-1 RAs

26. Basal Insulin/GLP-1 RA FRC Agents: Available in Prefilled Pens

27. Minimizing the Risk of Nausea When Adding a GLP-1 RA to Basal Insulin

28. Understanding the Role of Basal Insulin/GLP-1 RA FRC Agents In T2DM Management

29. Using Basal Insulin/GLP-1 RA FRC Therapy in Clinical Practice -- IDegLira

30. Using Basal Insulin/GLP-1 RA FRC Therapy in Clinical Practice -- IGlarLixi

31. Switching to Basal Insulin/GLP-1 RA FRC Therapy: Practical Considerations

32. Switching to Basal Insulin/GLP-1 RA FRC Therapy: Practical Considerations (cont)

33. IGlarLixi: Method of Administration

34. Insulin Dose

35. Basal Insulin/GLP-1 RA FRC Therapy: Future Considerations

36. Summary

37. Abbreviations